Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche has launched an expansive Phase III program for the glycine reuptake inhibitor RG1678 for both positive and negative symptoms of the disease.